Table 2. Association measurements for studies analyzing the effects of CYP2D6 on tamoxifen outcomes.
| Author, Year | Country | Ethnicity | Major Variant Allele | RR/OR/HR | 95% CI | Sample size |
|---|---|---|---|---|---|---|
| Hertz et al. (2017)24 | USA | Caucasian | *2; *4; *41 | RR 0.44 | 0.22–0.98 | 957 |
| Teh et al. (2011)25 | Malaysia | Malaysian Malay | *10 | OR 9.9 | 2.11–46.6 | 95 |
| Lan et al. (2018)16 | China | Chinese | *10 | HR 1.87 | 1.19–2.93 | 778 |
| Wegman et al. (2005)22 | Sweden | Caucasian | *4 | RR 0.28 | 0.21–1.12 | 226 |
| Nowell et al. (2005)23 | USA | Caucasian, African-Americans | *4 | HR 0.77 | 0.32–1.81 | 337 |
| Motamedi et al. (2013)30 | Iran | - | - | OR 1.6‡ | 0.53–4.78 | 79 |
Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio; RR, relative risk; USA, United States of America.
‡
OR for tamoxifen resistance for the presence of three CYP2D6 copies.